2003
DOI: 10.1128/aac.47.9.2770-2774.2003
|View full text |Cite
|
Sign up to set email alerts
|

Randomized Double-Blind Study Comparing 3- and 6-Day Regimens of Azithromycin with a 10-Day Amoxicillin-Clavulanate Regimen for Treatment of Acute Bacterial Sinusitis

Abstract: A randomized, double-blind, multicenter study of adults with acute bacterial sinusitis (ABS) compared the efficacy and safety of two azithromycin (AZM) regimens, 500 mg/day once daily for 3 days (AZM-3) or 6 days (AZM-6) to the efficacy and safety of an amoxicillin-clavulanate (AMC) regimen of 500-125 mg three times daily for 10 days. A total of 936 subjects with clinically and radiologically documented ABS were treated (AZM-3, 312; AZM-6, 311; AMC, 313). Clinical success rates were equivalent among per-protoc… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

2
38
3
5

Year Published

2004
2004
2016
2016

Publication Types

Select...
7
2

Relationship

0
9

Authors

Journals

citations
Cited by 34 publications
(48 citation statements)
references
References 12 publications
2
38
3
5
Order By: Relevance
“…In a study the efficacy and side effects of 500 mg azithromycin taken daily for 3 and 6 days were compared with those of co-amoxiclav 500/125 mg taken 3 times a day for 10 days with regard to treatment of acute sinusitis in adults . The efficacy of azithromycin was obtained 88.8% and 89.3% for 3 and 6 days, respectively, and that of co-amoxiclav was reported 84.9% (Henry, Riffer, Sokol, Chaudry, & Swanson, 2003). In our study, the cure rate in azithromycin group was 88% and in co amoxiclav group was 83/3% at tenth day, this shows our findings are in line with this study.…”
Section: Discussionsupporting
confidence: 83%
“…In a study the efficacy and side effects of 500 mg azithromycin taken daily for 3 and 6 days were compared with those of co-amoxiclav 500/125 mg taken 3 times a day for 10 days with regard to treatment of acute sinusitis in adults . The efficacy of azithromycin was obtained 88.8% and 89.3% for 3 and 6 days, respectively, and that of co-amoxiclav was reported 84.9% (Henry, Riffer, Sokol, Chaudry, & Swanson, 2003). In our study, the cure rate in azithromycin group was 88% and in co amoxiclav group was 83/3% at tenth day, this shows our findings are in line with this study.…”
Section: Discussionsupporting
confidence: 83%
“…While the incidence of treatment-related diarrhea (12.3%) was higher in the azithromycin treatment arm than in the amoxicillin/clavulanate arm, it is lower than the rate of treatment-related diarrhea reported in a study of the recently approved 3-day azithromycin regimen for bacterial sinusitis (17.0%) (12). The overall difference in treatment-related adverse events between treatments was primarily due to diarrhea, since the number of patients with adverse events other than diarrhea was only slightly higher for azithromycin-treated patients.…”
Section: Discussionmentioning
confidence: 46%
“…This base model was then expanded in a third step to link changes in the free plasma concentrations over time to the corresponding free tissue concentrations (cf. equation 2), with the concentrations calculated as the ratio of the amount and the respective tissue volume: (2) where k in and k out are the first-order rate constants describing the distribution of AZM in and out of the tissue, respectively. Given the affinity of protonated AZM to negatively charged phospholipids ( …”
Section: Methodsmentioning
confidence: 99%
“…A zithromycin (AZM) is a semisynthetic macrolide antibiotic with a broad range of activity against Gram-positive bacteria and some community-acquired Gram-negative pathogens, including Haemophilus influenzae and Moraxella catarrhalis, and it is extensively used in the clinic setting for the treatment of respiratory tract infections (1,2). Compared to the older macrolides, AZM is thought to have advantageous pharmacokinetic (PK) and pharmacodynamic (PD) properties, particularly due to its large distribution volume (ϳ23 liter/kg of body weight) and long halflife of 68 to 79 h (3), which allows for a convenient once-daily dosing regimen and a short overall duration of treatment of 3 to 5 days (4).…”
mentioning
confidence: 99%